RxDoctor Payments Data

Marilyn Cherry-Burkett

Nurse Practitioner · Dothan, ALNPI 1730385451

Payments from drug & device makers

$5,670in general payments, 2019–2025

Across 216 payments — averaging $26.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Novo Nordisk$931
  • Dexcom, Inc.$486
  • Lilly USA, LLC$364
  • Abbott$325
  • Bayer$172
  • plus $1K from 28 others

What the payments were for

  • Consulting fees$701%
  • Travel & lodging$1,07319%
  • Food & beverage$4,47579%
  • Other$521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,670 in reported general payments places this provider in the 90th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide384$632,438
Tresiba Flextouch U-200Insulin Degludec169$340,296
MounjaroTirzepatide177$248,029
TrulicityDulaglutide82$104,291
Humalog Kwikpen U-200Insulin Lispro25$99,535
Tresiba Flextouch U-100Insulin Degludec96$96,013
JardianceEmpagliflozin107$94,455
Lyumjev Kwikpen U-100Insulin Lispro-Aabc42$73,961
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog41$62,660
FarxigaDapagliflozin Propanediol49$46,657
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog63$46,539
Humalog Kwikpen U-100Insulin Lispro72$39,096
JanuviaSitagliptin Phosphate34$37,369
Fiasp FlextouchInsulin Aspart (Niacinamide)28$31,518
InvokanaCanagliflozin24$25,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp, Novolog$931$667,026423 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro, Humulin 70-30$364$378,283345 claims
Boehringer IngelheimJardiance, Tradjenta$47$119,524135 claims
MerckJanuvia, Janumet Xr$12$59,53159 claims
AstraZenecaFarxiga$87$46,65749 claims
Johnson & JohnsonInvokana$21$25,31324 claims
Sanofi-aventis U.S. LLCLantus$63$6,31923 claims
AbbVieSynthroid$148$2,73121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →